Mobile

An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000144-92

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of AMG 531 in thrombocytopenic subjects with low or Intermediate-1 risk MDS.

Critère d'inclusion

  • Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Liens